Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALEC Alector	$2.18 +9.0%	$1.60	$0.87 ▼ $6.37	$202.42M	0.86	1.19 million shs	1.55 million shs
ARVN Arvinas	$7.09 +4.4%	$7.51	$5.90 ▼ $29.61	$498.51M	2.22	2.18 million shs	2.63 million shs
IOVA Iovance Biotherapeutics	$2.46 +10.1%	$2.25	$1.64 ▼ $12.51	$806.93M	0.88	26.90 million shs	15.23 million shs
SAGE Sage Therapeutics	$8.68	$8.68	$4.62 ▼ $11.44	$543.54M	0.26	3.63 million shs	N/A

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALEC Alector	+8.95%	+52.38%	+30.48%	+97.19%	-57.02%
ARVN Arvinas	+4.42%	+10.26%	-9.91%	+13.26%	-70.68%
IOVA Iovance Biotherapeutics	+10.09%	-4.84%	+22.14%	+39.49%	-77.14%
SAGE Sage Therapeutics	0.00%	0.00%	-5.14%	+31.32%	+6.63%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALEC Alector	4.0968 of 5 stars	3.1	3.0	4.5	3.0	2.5	0.0
ARVN Arvinas	3.6778 of 5 stars	4.3	2.0	0.0	2.8	2.5	1.3
IOVA Iovance Biotherapeutics	4.1115 of 5 stars	3.2	1.0	4.2	2.2	4.2	0.6
SAGE Sage Therapeutics	3.8368 of 5 stars	2.0	5.0	4.1	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALEC Alector	2.29	Hold	$4.17	91.22% Upside
ARVN Arvinas	2.55	Moderate Buy	$19.76	178.75% Upside
IOVA Iovance Biotherapeutics	2.38	Hold	$11.90	384.73% Upside
SAGE Sage Therapeutics	1.93	Reduce	$7.85	-9.56% Downside

Current Analyst Ratings Breakdown

Latest ALEC, IOVA, ARVN, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$18.00 ➝ $14.00
8/8/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$25.00 ➝ $20.00
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
7/28/2025	ALEC Alector	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Outperform	$2.50 ➝ $3.50
7/23/2025	IOVA Iovance Biotherapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
7/15/2025	IOVA Iovance Biotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Sell
7/8/2025	SAGE Sage Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$12.00 ➝ $9.20
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50

(Data available from 8/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALEC Alector	$81.13M	2.72	N/A	N/A	$0.70 per share	3.11
ARVN Arvinas	$263.40M	1.98	N/A	N/A	$8.30 per share	0.85
IOVA Iovance Biotherapeutics	$164.07M	5.41	N/A	N/A	$1.93 per share	1.27
SAGE Sage Therapeutics	$41.24M	13.18	N/A	N/A	$5.89 per share	1.47

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALEC Alector	-$119.05M	-$1.16	N/A	N/A	N/A	-142.10%	-112.06%	-26.37%	N/A
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
IOVA Iovance Biotherapeutics	-$372.18M	-$1.23	N/A	N/A	N/A	-161.44%	-52.87%	-41.31%	N/A
SAGE Sage Therapeutics	-$400.67M	-$4.89	N/A	N/A	N/A	-427.78%	-67.10%	-58.42%	N/A

Latest ALEC, IOVA, ARVN, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ALEC Alector	-$0.45	-$0.30	+$0.15	-$0.30	$2.76 million	$7.87 million
8/7/2025	Q2 2025	IOVA Iovance Biotherapeutics	-$0.29	-$0.33	-$0.04	-$0.33	$67.14 million	$59.95 million
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million
7/30/2025	Q2 2025	SAGE Sage Therapeutics	-$0.96	-$0.79	+$0.17	-$0.79	$16.69 million	$31.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALEC Alector	N/A	N/A	N/A	N/A	N/A
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALEC Alector	0.13	3.78	3.78
ARVN Arvinas	N/A	5.64	5.64
IOVA Iovance Biotherapeutics	N/A	3.27	2.89
SAGE Sage Therapeutics	N/A	9.16	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALEC Alector	85.83%
ARVN Arvinas	95.19%
IOVA Iovance Biotherapeutics	77.03%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
ALEC Alector	9.70%
ARVN Arvinas	4.73%
IOVA Iovance Biotherapeutics	10.30%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALEC Alector	270	101.21 million	91.39 million	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
IOVA Iovance Biotherapeutics	500	361.85 million	324.58 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

ALEC, IOVA, ARVN, and SAGE Headlines

Recent News About These Companies

Why Are Supernus Pharmaceuticals (SUPN) Shares Soaring Today

August 6, 2025 | finance.yahoo.com

GSA Capital Partners LLP Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

August 5, 2025 | marketbeat.com

Federated Hermes Inc. Increases Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

August 3, 2025 | marketbeat.com

Wall Street Zen Upgrades Sage Therapeutics (NASDAQ:SAGE) to Hold

August 2, 2025 | marketbeat.com

Sage (SAGE) Q2 Revenue Jumps 264%

August 1, 2025 | aol.comA

Supernus strengthens neuropsychiatric portfolio with Sage Therapeutics

August 1, 2025 | finance.yahoo.com

Sage Therapeutics, Inc. (NASDAQ:SAGE) Receives Average Rating of "Reduce" from Brokerages

July 31, 2025 | marketbeat.com

Sage Therapeutics Announces Second Quarter 2025 Financial Results

July 31, 2025 | finance.yahoo.com

Sage Therapeutics, Inc. (SAGE) Reports Q2 Loss, Beats Revenue Estimates

July 30, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Sees Strong Trading Volume - Time to Buy?

July 30, 2025 | marketbeat.com

Monaco Asset Management SAM Takes $3.51 Million Position in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 30, 2025 | marketbeat.com

Cerity Partners LLC Purchases New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 27, 2025 | marketbeat.com

BML Capital Management LLC Buys New Shares in Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 26, 2025 | marketbeat.com

Europe's CHMP gives thumbs up to Lilly's Kisunla and Gilead's long-acting PrEP drug Yeytuo

July 25, 2025 | fiercepharma.comF

Cwm LLC Acquires 58,410 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)

July 25, 2025 | marketbeat.com

Sage Therapeutics (SAGE) Expected to Announce Earnings on Wednesday

July 23, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Sees Large Volume Increase - What's Next?

July 22, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Shares Pass Above Fifty Day Moving Average - Should You Sell?

July 16, 2025 | marketbeat.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

July 14, 2025 | businesswire.com

Beyond The Numbers: 6 Analysts Discuss Sage Therapeutics Stock

July 9, 2025 | nasdaq.com

Scotiabank Downgrades Sage Therapeutics (SAGE)

July 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALEC, IOVA, ARVN, and SAGE Company Descriptions

Alector NASDAQ:ALEC

$2.18 +0.18 (+8.95%)

Closing price 08/13/2025 03:59 PM Eastern

Extended Trading

$2.15 -0.02 (-1.10%)

As of 05:33 AM Eastern

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

Arvinas NASDAQ:ARVN

$7.09 +0.30 (+4.42%)

Closing price 08/13/2025 04:00 PM Eastern

Extended Trading

$7.04 -0.05 (-0.71%)

As of 08/13/2025 07:52 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Iovance Biotherapeutics NASDAQ:IOVA

$2.46 +0.23 (+10.09%)

Closing price 08/13/2025 03:59 PM Eastern

Extended Trading

$2.44 -0.02 (-0.77%)

As of 05:43 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Sage Therapeutics NASDAQ:SAGE

$8.68 0.00 (0.00%)

As of 07/31/2025

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time